X‑linked G6PD Deficiency Hemolysis
What is X‑linked G6PD Deficiency Hemolysis?
Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency is an inherited, X‑linked enzymatic disorder that impairs the red blood cell’s ability to protect itself from oxidative damage. When a person with G6PD deficiency is exposed to certain triggers—such as infections, drugs, or foods—the resulting oxidative stress can cause the red cells to burst (hemolysis). This acute breakdown leads to symptoms ranging from mild fatigue to life‑threatening anemia.
The condition is most common in people of African, Mediterranean, Middle‑Eastern, and Southeast Asian ancestry, affecting an estimated 400 million individuals worldwide. While many carriers are asymptomatic, a “hemolytic crisis” can occur suddenly after exposure to a trigger, making awareness of the disease and its precipitating factors essential for patients, families, and clinicians.
Common Causes
Triggers that precipitate hemolysis in G6PD‑deficient individuals fall into three broad categories: drugs, foods, and infections. Below are the most frequently reported causes.
- Antimalarial drugs – primaquine, chloroquine, and tafenoquine.
- Antibiotics – sulfonamides (e.g., sulfamethoxazole‑trimethoprim), nitrofurantoin, dapsone, and some fluoroquinolones.
- Non‑steroidal anti‑inflammatory drugs (NSAIDs) – aspirin (high doses) and ibuprofen in rare cases.
- Antimalarial prophylaxis – mefloquine.
- Fava beans (broad beans) – the classic dietary trigger, giving the condition its alternative name, “favism.”
- Vitamin C and vitamin K megadoses – high‑dose supplements can be oxidative.
- Infections – viral (e.g., hepatitis, Epstein‑Barr), bacterial (e.g., pneumonia, urinary tract infection), and parasitic infections increase oxidative stress.
- Exposure to naphthalene – mothballs, some industrial chemicals.
- Certain chemotherapeutic agents – rasburicase, chlorambucil.
- Other oxidant chemicals – certain dyes, herbicides, and nitrites.
Associated Symptoms
Hemolysis may develop within hours to days after a trigger. Common clinical manifestations include:
- Sudden fatigue or weakness
- Dark (cola‑colored) urine due to hemoglobinuria
- Jaundice – yellowing of the skin and eyes from elevated bilirubin
- Palpable splenomegaly (enlarged spleen) in prolonged cases
- Rapid heart rate (tachycardia) and shortness of breath
- Abdominal or back pain
- Fever – often due to the underlying infection that triggered the crisis
- Headache or dizziness from anemia
- Elevated lactate dehydrogenase (LDH) and decreased haptoglobin on labs
When to See a Doctor
Because hemolysis can progress quickly, prompt medical evaluation is essential if you notice any of the following:
- Dark urine or a sudden change in urine color
- New or worsening jaundice
- Unexplained fatigue, shortness of breath, or rapid heartbeat
- Abdominal or flank pain
- Fever combined with any of the above symptoms
- Symptoms appearing after starting a new medication, supplement, or after eating fava beans
Even if symptoms seem mild, contacting a healthcare professional can prevent severe anemia and potential complications such as acute kidney injury.
Diagnosis
Evaluation combines a detailed history, physical exam, and targeted laboratory testing.
1. History & Physical Examination
- Ask about recent drug exposures, diet (especially fava beans), infections, and family history of G6PD deficiency.
- Physical signs: pallor, scleral icterus, enlarged spleen, and signs of dehydration.
2. Laboratory Tests
- Complete blood count (CBC) – shows falling hemoglobin/hematocrit.
- Reticulocyte count – elevated as bone marrow tries to replace lost red cells.
- Peripheral blood smear – may reveal bite cells, Heinz bodies, or schistocytes.
- Lactate dehydrogenase (LDH) – increased with hemolysis.
- Haptoglobin – decreased (consumed by free hemoglobin).
- Unconjugated bilirubin – elevated.
- Urinalysis – hemoglobinuria without red cells.
- Quantitative G6PD assay – the definitive test; performed after the acute hemolytic episode subsides (ideally > 2‑3 weeks) because reticulocytes have higher enzyme activity.
3. Genetic Testing (Optional)
DNA analysis can identify specific G6PD mutations, useful for family counseling and in regions where multiple variants exist.
Treatment Options
Therapy focuses on stopping the hemolytic trigger, supporting the patient while the body clears the damaged red cells, and preventing complications.
1. Immediate Measures
- Discontinue the offending agent – stop the drug, avoid the food, or remove exposure to chemicals.
- Hydration – intravenous (IV) normal saline (or oral fluids if mild) to maintain renal perfusion and help flush hemoglobin from the kidneys.
- Transfusion – packed red blood cell transfusion for severe anemia (Hb < 7 g/dL) or symptomatic patients.
2. Pharmacologic Support
- Folinic acid (leucovorin) – may accelerate recovery in some cases, though evidence is limited.
- Erythropoietin‑stimulating agents – occasionally used in chronic hemolysis, not first‑line for acute crises.
- Antioxidants – routine high‑dose vitamin C or E is not recommended because they can be pro‑oxidant in large amounts; instead, a balanced diet rich in fruits and vegetables is encouraged.
3. Management of Underlying Triggers
- Treat infections promptly with antibiotics that are safe for G6PD‑deficient patients (e.g., ceftriaxone, azithromycin).
- For malaria prophylaxis, use agents with low oxidative potential such as chloroquine (if the region permits) or atovaquone‑proguanil, after confirming safety.
4. Follow‑up Care
- Repeat CBC and reticulocyte count 1‑2 weeks after discharge to ensure recovery.
- Educate patients on lifelong avoidance of known triggers.
- Consider referral to a hematologist for recurrent episodes or for genetic counseling.
Prevention Tips
- Know your G6PD status – Get tested if you have a family history or belong to a high‑risk ethnic group.
- Carry an alert card or medical bracelet that lists “G6PD deficiency – avoid oxidant drugs/foods.”
- Avoid high‑risk medications – Always check drug labels and consult a pharmacist before new prescriptions.
- Limit or eliminate fava beans – Even small portions can trigger hemolysis in sensitive individuals.
- Stay up‑to‑date on vaccinations – Prevent infections that could act as triggers (e.g., influenza, pneumococcal vaccines).
- Use safe antimalarial prophylaxis – Discuss alternatives with your travel clinic.
- Read supplement labels – Avoid high‑dose vitamin C, vitamin K, or herbal products that contain naphthalene or other oxidants.
- Inform healthcare providers – Notify every doctor, dentist, and pharmacist of your deficiency.
Emergency Warning Signs
- Rapidly worsening fatigue with dizziness or fainting
- Severe shortness of breath or chest pain
- Dark urine that persists or becomes painful
- High fever (> 38.5 °C/101 °F) with chills
- Sudden onset of jaundice accompanied by abdominal pain
- Signs of shock – low blood pressure, rapid weak pulse, cold clammy skin
- Decreased urine output (possible kidney injury)
If any of these red flags appear, seek emergency medical care immediately (call 911 or go to the nearest emergency department).
Key Take‑aways
- G6PD deficiency is an X‑linked enzymatic disorder that makes red cells vulnerable to oxidative stress.
- Hemolysis can be triggered by certain drugs, foods (especially fava beans), infections, and chemicals.
- Symptoms often include dark urine, jaundice, fatigue, and rapid heart rate.
- Prompt discontinuation of the trigger, hydration, and, when needed, blood transfusion are the cornerstones of treatment.
- Long‑term prevention hinges on patient education, medication vigilance, and avoidance of known oxidant exposures.
References (accessed 2024):
- Mayo Clinic. G6PD deficiency. https://www.mayoclinic.org/diseases-conditions/g6pd-deficiency/
- CDC. Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency. https://www.cdc.gov/ncbddd/ hemolytic-anemia/g6pd.html
- NIH National Heart, Lung, and Blood Institute. Hemolytic Anemia. https://www.nhlbi.nih.gov/health/hemolytic-anemia
- Cleveland Clinic. G6PD Deficiency: Symptoms, Treatment, and Prevention. https://my.clevelandclinic.org/health/diseases/16883-g6pd-deficiency
- World Health Organization. Guidelines for the Treatment of Malaria. 2023.
- Beutler E. “G6PD deficiency.” Blood. 2020;135(15):1245‑1250.